Adial Pharmaceuticals Inc (ADIL)
$0.95
Performance
- $0.95$0.98$0.95
0.05%
Downside
Day's Volatility :3.11%
Upside
3.06%
- $0.77$4.17$0.95
19.47%
Downside
52 Weeks Volatility :81.65%
Upside
77.22%
Returns
| Period | Adial Pharmaceuticals Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -15.93% | 0.0% |
6 Months | -59.23% | 0.0% |
1 Year | -67.58% | 0.0% |
3 Years | -98.98% | -20.8% |
Highlights
Market Capitalization | 6.1M |
Book Value | $1.0 |
Earnings Per Share (EPS) | -3.99 |
Wall Street Target Price | 7.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -104.18% |
Return On Equity TTM | -320.96% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -7.3M |
Diluted Eps TTM | -3.99 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.89 |
EPS Estimate Next Year | -1.16 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 689.47%
Technicals Summary
Sell
Neutral
Buy
Adial Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Adial Pharmaceuticals Inc | -12.84% | -59.23% | -67.58% | -98.98% | -97.34% |
 Regeneron Pharmaceuticals, Inc. | -12.78% | 12.27% | 21.13% | 86.55% | 232.53% |
 Novo Nordisk A/s | -12.16% | -3.59% | 19.82% | 145.88% | 361.43% |
 Alnylam Pharmaceuticals, Inc. | 8.63% | 91.46% | 72.01% | 39.76% | 259.26% |
 Vertex Pharmaceuticals Incorporated | -0.52% | 20.07% | 29.39% | 164.22% | 174.3% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Adial Pharmaceuticals Inc | 0.02 | NA | NA | -2.89 | -3.21 | -1.04 | NA | 1.0 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.38 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.58 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Adial Pharmaceuticals Inc | Buy | $6.1M | -97.34% | 0.02 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 232.53% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 361.43% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $36.5B | 259.26% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $122.9B | 174.3% | 32.84 | -4.74% |
Insights on Adial Pharmaceuticals Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.0% return, outperforming this stock by 139.6%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 39.8% return, outperforming this stock by 138.8%
Institutional Holdings
UBS Group AG
1.31%Manchester Capital Management LLC
0.75%Renaissance Technologies Corp
0.54%HRT FINANCIAL LLC
0.46%BlackRock Inc
0.43%Geode Capital Management, LLC
0.40%
Company Information
adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.
Organization | Adial Pharmaceuticals Inc |
Employees | 4 |
CEO | Mr. Cary John Claiborne MBA |
Industry | Health Technology |
Discover More
Metal Sky Star Acquisition Corp
$0.95
+0.0%
Stone Ridge 2054 Longevity Income Etf
$0.95
+0.0%
International Money Express
$0.95
+0.0%
Nabors Energy Transition Corp Ii
$0.95
+0.0%
Western Asset High Income Fund Ii Inc
$0.95
+0.0%
Dimensional Us Core Equity 1 Etf
$0.95
+0.0%
Natuzzi Spa
$0.95
+0.0%
Swan Hedged Equity Us Lg Cap
$0.95
+0.0%
Jpmorgan Activebuilders Emer
$0.95
+0.0%